NASDAQ: BLTEBelite Bio Inc Stock
$164.11-5.44 (-3.21%)
Updated Mar 13, 2026
BLTE Price
$164.11
Fair Value Price
N/A
Market Cap
$5.22B
52 Week Low
$49.00
52 Week High
$200.00
P/E
N/A
P/B
19.06x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.03
Operating Cash Flow
N/A
Beta
0.21
Next Earnings
Mar 27, 2026
Ex-Dividend
N/A
Next Dividend
N/A
BLTE Overview
Belite Bio, Inc is a clinical-stage biopharmaceutical drug development company. The company's pipeline of therapies is built on its RBP4 (Retinol Binding Protein 4) IP portfolio. Belite Bio is focused on meeting the unmet needs of patients suffering from blindness, liver disease, and diabetes. The company operates as a subsidiary of Lin Bioscience International Ltd. Belite Bio was founded in 2016 and is based in San Diego, CA.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine BLTE's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +7.53% per year. Learn More
Zen Rating Component Grades
D
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
BLTE
Ranked#235 of 469
Ranked#235 of 469
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $14.51 | A | |
| $32.13 | A | |
| $178.55 | A |
Be the first to know about important BLTE news, forecast changes, insider trades & much more!
BLTE News
Overview
Due Diligence Score
–
Industry Average (25)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how BLTE scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
BLTE is poor value based on its book value relative to its share price (19.06x), compared to the US Biotechnology industry average (4.7x)
P/B vs Industry Valuation
BLTE's short-term assets ($277.21M) exceed its short-term liabilities ($8.07M)
Short-term Liabilities Financials
BLTE's short-term assets ($277.21M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
There are 30 more BLTE due diligence checks available for Premium users.
Valuation
BLTE fair value
Fair Value of BLTE stock based on Discounted Cash Flow (DCF)
Price
$164.11
Fair Value
$1.02
Overvalued by
15,993.94%
BLTE price to earnings (PE)
For valuing profitable companies with steady earnings
Company
0x
Industry
29.31x
Market
31.82x
BLTE price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
19.06x
Industry
4.7x
BLTE is poor value based... subscribe to Premium to read more.
P/B vs Industry Valuation
BLTE's financial health
Profit margin
Revenue
$0.0
Net Income
$0.0
Profit Margin
0%
Assets to liabilities
Assets
$282.4M
Liabilities
$8.3M
Debt to equity
0.03
BLTE's short-term assets ($277.21M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
BLTE's short-term assets ($277.21M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
BLTE's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
N/A
Investing
N/A
Financing
N/A
BLTE vs Biotech Stocks
Belite Bio Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.